NCT03022500View on ClinicalTrials.gov

Pulmonary sarcomatoid_MEDI4736+Treme

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

November 30, 2019

Conditions
Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Interventions
DRUG

durvalumab + tremelimumab

Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.

Trial Locations (1)

110-744

Department of Internal Medicine, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT03022500 - Pulmonary sarcomatoid_MEDI4736+Treme | Biotech Hunter | Biotech Hunter